Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Echocardiographic phenotype for refined risk stratification and treatment selection in light chain amyloidosis with heart failure.

Journal of cancer research and clinical oncology - 1 Sept 2023

Yang Hong, Li Rui, Ma Fei, Liu Yujian, He Xingwei, Yang Qiao, Wang Dao Wen, Zeng Hesong, Wang Hong

Abstract excerpt

AIMS: Light chain amyloidosis (AL) patients with heart failure (HF) are usually with revised Mayo (rMayo) stage III/IV disease and have a poor prognosis. We sought to investigate whether and what echocardiographic phenotype provides value for further risk stratification and guiding optimal risk-adapted treatment in this subgroup of AL patients. METHODS AND RESULTS: 95 AL patients who presented with HF and were on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis
Share to Echocardiography

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Failure

Share to Phenotype

Share to Prognosis

Share to Risk Assessment

Share to Stroke Volume

Share to Ventricular Function, Left

Source

Identifiers

PMID: 37084113
DOI: 10.1007/s00432-023-04783-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Echocardiographic phenotype for refined risk stratification and treatment selection in light chain amyloidosis with heart failure.PMID 37084113Read ↗

Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction.Semantic proximity Read ↗

Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis.Semantic proximity Read ↗

Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.Semantic proximity Read ↗

Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.Semantic proximity Read ↗

Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy.Semantic proximity Read ↗

Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study.Semantic proximity Read ↗

Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.Semantic proximity Read ↗

Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis.Semantic proximity Read ↗

Cardiac Care of Patients with Cardiac Amyloidosis.Semantic proximity Read ↗

Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction.Semantic proximity Read ↗

Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.Semantic proximity Read ↗

Pathophysiology and treatment of cardiac amyloidosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.